Paradigm Biocapital Advisors
Latest statistics and disclosures from Paradigm Biocapital Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NUVL, ACLX, ARGX, IRON, LEGN, and represent 42.11% of Paradigm Biocapital Advisors's stock portfolio.
- Added to shares of these 10 stocks: NUVL (+$163M), IRON (+$64M), Ambrx Biopharma (+$64M), ARGX (+$61M), ASND (+$44M), ACLX (+$39M), ARVN (+$38M), XENE (+$29M), VRDN (+$24M), TARS (+$21M).
- Started 7 new stock positions in ASND, ARVN, AVTE, CRGX, Ambrx Biopharma, TARS, ZNTL.
- Reduced shares in these 10 stocks: , , Ambrx Biopharma (-$43M), SNDX (-$35M), TGTX (-$25M), VRNA (-$15M), ROIV (-$13M), AUTL (-$12M), CERE (-$8.6M), LEGN (-$7.9M).
- Sold out of its positions in Ambrx Biopharma, COGT, ETNB, INCY, SNDX, UTHR, VRNA, ROIV.
- Paradigm Biocapital Advisors was a net buyer of stock by $306M.
- Paradigm Biocapital Advisors has $2.1B in assets under management (AUM), dropping by 44.94%.
- Central Index Key (CIK): 0001855655
Tip: Access up to 7 years of quarterly data
Positions held by Paradigm Biocapital Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Paradigm Biocapital Advisors
Paradigm Biocapital Advisors holds 29 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Nuvalent Inc-a (NUVL) | 13.3 | $284M | +135% | 3.9M | 73.59 |
|
| Arcellx Common Stock (ACLX) | 9.5 | $203M | +23% | 3.7M | 55.50 |
|
| Argenx Se Sponsored Adr (ARGX) | 7.5 | $161M | +61% | 423k | 380.43 |
|
| Disc Medicine (IRON) | 6.5 | $138M | +87% | 2.4M | 57.76 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 5.3 | $114M | -6% | 1.9M | 60.17 |
|
| Olema Pharmaceuticals (OLMA) | 5.2 | $111M | 7.9M | 14.03 |
|
|
| Miragen Therapeutics (VRDN) | 4.9 | $104M | +30% | 4.8M | 21.78 |
|
| Immunocore Hldgs Ads (IMCR) | 4.7 | $99M | +4% | 1.5M | 68.32 |
|
| Cerevel Therapeutics Hldng I (CERE) | 4.6 | $99M | -7% | 2.3M | 42.40 |
|
| Xenon Pharmaceuticals (XENE) | 4.6 | $98M | +42% | 2.1M | 46.06 |
|
| Mirati Therapeutics | 4.2 | $91M | -7% | 1.5M | 58.75 |
|
| Crinetics Pharmaceuticals In (CRNX) | 3.9 | $82M | +6% | 2.3M | 35.58 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 3.8 | $81M | -12% | 13M | 6.44 |
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 3.1 | $67M | 3.7M | 18.08 |
|
|
| Ambrx Biopharma Call Option | 3.0 | $64M | NEW | 4.5M | 14.24 |
|
| Alpine Immune Sciences (ALPN) | 2.8 | $61M | +31% | 3.2M | 19.06 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 2.1 | $44M | NEW | 352k | 125.95 |
|
| Arvinas Ord (ARVN) | 1.8 | $38M | NEW | 931k | 41.16 |
|
| Tg Therapeutics (TGTX) | 1.7 | $37M | -39% | 2.2M | 17.08 |
|
| Zai Lab Adr (ZLAB) | 1.4 | $30M | -4% | 1.1M | 27.33 |
|
| Immatics SHS (IMTX) | 1.1 | $23M | +3% | 2.1M | 10.53 |
|
| Tarsus Pharmaceuticals (TARS) | 1.0 | $21M | NEW | 1.0M | 20.25 |
|
| Compass Pathways Sponsored Ads (CMPS) | 0.9 | $20M | +66% | 2.3M | 8.75 |
|
| Kura Oncology (KURA) | 0.9 | $18M | +4% | 1.3M | 14.38 |
|
| Caribou Biosciences (CRBU) | 0.8 | $17M | 2.9M | 5.73 |
|
|
| Vor Biopharma (VOR) | 0.7 | $15M | 6.5M | 2.25 |
|
|
| Cargo Therapeutics (CRGX) | 0.4 | $7.7M | NEW | 333k | 23.15 |
|
| Zentalis Pharmaceuticals (ZNTL) | 0.3 | $6.1M | NEW | 400k | 15.15 |
|
| Aerovate Therapeutics (AVTE) | 0.2 | $3.2M | NEW | 143k | 22.63 |
|
Past Filings by Paradigm Biocapital Advisors
SEC 13F filings are viewable for Paradigm Biocapital Advisors going back to 2021
- Paradigm Biocapital Advisors 2023 Q4 filed Feb. 14, 2024
- Paradigm Biocapital Advisors 2023 Q3 filed Nov. 14, 2023
- Paradigm Biocapital Advisors 2023 Q2 filed Aug. 14, 2023
- Paradigm Biocapital Advisors 2023 Q1 filed May 15, 2023
- Paradigm Biocapital Advisors 2022 Q4 filed Feb. 14, 2023
- Paradigm Biocapital Advisors 2022 Q3 filed Nov. 14, 2022
- Paradigm Biocapital Advisors 2022 Q2 filed Aug. 15, 2022
- Paradigm Biocapital Advisors 2022 Q1 filed May 16, 2022
- Paradigm Biocapital Advisors 2021 Q4 filed Feb. 14, 2022